Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy

American Journal of Managed Care

Volumn 5, Issue 5, 1999, Pages 631-638

  Condra, Laura J ^a,b   Morreale, Anthony P ^a   Stolley, Stephen N ^a   Marcus, David ^a  

^a Veteran Aff S Diego Hlthcare S ^*  (United States)

^b Pharmacy Service (119)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG COST; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRIORITY JOURNAL; SCORING SYSTEM; SYMPTOMATOLOGY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; FORMULARIES, HOSPITAL; GASTROESOPHAGEAL REFLUX; HEALTH CARE SURVEYS; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT SATISFACTION; QUESTIONNAIRES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0032983805     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Spechler SJ. Epidemiology and natural history of gastrooesophageal reflux disease. Digestion 1992;51:21-29.
2. DeVault KR, Castrell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994;69:867-876.
3. Richter JE. Long-term management of gastroesophageal reflux disease and its complications. Am J Gastroenterol 1997;92(4):30S-34S.
4. Garnett WR. Efficacy, safety, cost issues in managing patients with gastroesophageal reflux disease. Am J Hosp Pharm 1993;50(suppl 1):S11-S18.
5. Klinkenberg-Knol EC, Festen HPM, Jansen JMBJ, Meuwissen SGM, Lamers CBHW. Double blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oseophagitis. Lancet 1987;8529:349-351.
6. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988;23:625-632.
7. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts J-L. Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 1988;33:523-529.
8. Havelund T, Laursen LS, Skoubo-Kristensen E, et al. Omeprazole and ranitidine in treatment of reflux oesophagitis: Double-blind comparative trial. Br Med J 1988;296:89-92.
9. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole vs ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994;35:590-598.
10. Robinson M, Sahba B, Avner D, et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther 1995;9:25-31.
11. Gough AL, Long RG, Cooper BT, et al. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996;10:529-539.
12. Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. J Clin Gastroenterol 1995;20(suppl 1):S7-S9.
13. Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther 1996;10:757-763.
14. Vigneri S, Termini R, Leandro G, et al. A comparison of 5 maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110.
15. Vivian E, Morreale A, Hlavin P, et al. Clinical and pharmacoeconomic outcomes of lansoprazole versus omeprazole in symptomatic gastroesophageal reflux disease maintenance [abstract]. Pharmacotherapy 1998;18:43.
16. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993;28:224-228.
17. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch study group. Eur J Gastroenterol Hepatol 1996;8:1101-1106.
18. Vcev A, Stimac D, Vceva A, et al. Lansoprazole versus omeprazole in the treatment of reflux esophagitis. Acta Med Croatica 1997;51:171-174.
19. Bate CM, Richardson PD. A 1-year model for the cost effectiveness of treating reflux esophagitis. Br J Med Econ 1992;2:5-11.
20. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effectiveness analysis. Am J Gastroenterol 1997;12:2179-2187.